modelMedroxyprogesterone
Extends from Pharmacolibrary.Drugs.ATC.G.G03DA02.
Information
| name: | Medroxyprogesterone | |
| ATC code: | G03DA02 | route: | intramuscular |
| compartments: | 1 | |
| dosage: | 150 | mg |
| volume of distribution: | 20 | L |
| clearance: | 0.69 | L/h |
| other parameters in model implementation | ||
Medroxyprogesterone is a synthetic progestin, a derivative of progesterone, used primarily for hormone replacement therapy, treatment of endometriosis, dysmenorrhea, and as a component of some contraceptive formulations. It is available in both oral and injectable forms. Medroxyprogesterone acetate (MPA) is the main clinically used form. This drug is approved and in current therapeutic use.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult women following a single intramuscular dose of medroxyprogesterone acetate (Depo-Provera) 150 mg.
References
Zhou, XF, et al., & Sang, GW (1998). Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. Contraception 57(6) 405–411. DOI:10.1016/s0010-7824(98)00048-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9693401
Zahradnik, HP (1995). [Depot gestagens]. Archives of gynecology and obstetrics 257(1-4) 536–541. DOI:10.1007/BF02264884 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8579439
Longo, N, et al., & Sile, S (2014). Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet (London, England) 384(9937) 37–44. DOI:10.1016/S0140-6736(13)61841-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24743000
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)